Calithera Biosciences is Biotechnology in United States that focus on Calithera Biosciences Inc business. Founded in 2010. They cover business area such as Calithera Biosciences Inc, US, small molecule drug, tumor, immune cell target, key metabolic pathway, its lead product candidate, an inhibitor, glutaminase, its other product candidate, hematology and oncology indication.
2010
( 16 years old in 2026 )
Calithera Biosciences Inc
-
343 Oyster Point Boulevard
Suite 200
South San Francisco, CA 94080
United States
Private
Calithera Biosciences IncUSsmall molecule drugtumorimmune cell targetkey metabolic pathwayits lead product candidatean inhibitorglutaminaseits other product candidatehematology and oncology indication
* We use standard office opening hours in near Calithera Biosciences's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Calithera Biosciences is Biotechnology business from United States that founded in 2010 (16 years old in 2026), Calithera Biosciences business is focusing on Calithera Biosciences Inc.
Calithera Biosciences headquarter office and corporate office address is located in 343 Oyster Point Boulevard Suite 200 South San Francisco, CA 94080 United States.
Calithera Biosciences was founded in United States.
In 2026, Calithera Biosciences is currently focus on Calithera Biosciences Inc sector.
Above is snippet of Google Trends for "Calithera Biosciences Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Calithera Biosciences, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
